Special Issue

Non-Melanoma Skin Cancer: Promises and Challenges

Message from the Guest Editors

Non-melanoma skin cancer (NMSC)—which primarily includes basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)—is the most common form of cancer worldwide.

Management of NMSC is rapidly evolving, with a shift toward more personalized and less invasive approaches and increasing focus on early detection and immunotherapy for advanced disease. Despite these advances, significant challenges remain. The global incidence of NMSC continues to rise, and issues such as treatment resistance, long-term toxicity and disparities in access to care present ongoing obstacles. Addressing these complexities requires a multidisciplinary approach that integrates dermatology, medical oncology, radiation oncology, artificial intelligence (AI) and public health strategies.

This Special Issue aims to showcase original research articles, translational studies and reviews that highlight recent progress in the diagnosis, treatment and long-term management of NMSC.

Through this collection, we hope to provide a comprehensive overview of current advances and future directions in the field of NMSC.

Guest Editors

Dr. Francesca De Felice

Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza, "Sapienza" University of Rome, 00185 Rome, Italy

Dr. Valerio Nardone

Department of Precision Medicine, University of Campania "L. Vanvitelli", 80131 Naples, Italy

Deadline for manuscript submissions

30 April 2026



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/250597

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

